Clinical Trial Update: A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 prospective clinical trial is evaluating safety and efficacy of a triplet therapy (Irpagratinib, atezolizumab, and bevacizumab) in hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Irpagratinib

Snippet

Sponsor: Asan Medical Center | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: RECRUITING